Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-29
2008-07-29
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S506000
Reexamination Certificate
active
11048656
ABSTRACT:
The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
REFERENCES:
patent: 2680730 (1954-06-01), Elmore
patent: 3799969 (1974-03-01), Hoppe
patent: 4174398 (1979-11-01), Frohberger et al.
patent: 6037345 (2000-03-01), Pamukcu et al.
patent: 6838476 (2005-01-01), Almansa et al.
patent: 1205478 (2002-05-01), None
patent: WO 00/26203 (2000-05-01), None
patent: WO 01/12188 (2001-02-01), None
patent: WO 02/070494 (2002-09-01), None
Baracu et al., 1977, CAS: 87:183955/.
Johnston et al., 1967, CAS: 66:1279.
Abstract: Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt, Main, DE, Database Accession No. BRN 850669, 847575 (XP 002261772) (1988).
Abstract: Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE, Database Accession No. BRN 8288364, 8288635, 8288314 (XP 002261773) (2000).
Abstract: Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; Database Accession No. BRN 3385323 (XP 002261774) (1990).
Abstract: Database Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE; Database Accession No. BRN 2142974, 2153838, 214575 (XP 002261775) (1989).
Barton-Davis et al., “Aminoglycoside antibiotics restore dystrophin function to skeletal muscles ofmdxmice”,J. Clin. Invest. 104:375-381 (1999).
Baures, PW, et al., “Synthesis and Evaluation of Inhibitors of Transthyretin Amyloid Formation Based on the Non-Steroidal Anti-Inflammatory Drug, Flufenamic Acid”,Bioorganic and Medical Chemistry, 7:1339-1347 (1999).
Bedwell et al.,Nat. Med, “Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line”, 3:1280-1284 (1997).
Howard et al., “Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations”,Nat. Med. 2:467-469 (1996).
Nakao K, et al., “Quantitative Structure-Activity Analyses of Novel Hydroxyphenylurea Derivatives as Antioxidants”,Bioorganic&Medicinal Chemistry, Elsevier Science Ltd. GB, 6:6. pp. 849-868 (1998).
Sleat et al., “Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis”,Eur. J. Ped. Neurol. 5:Suppl. A. pp. 57-62 (2001).
Baracu et al., 1977, “Potential Anticancer Agents. XIII—Synthesis of New Alipathic and Cycloaliphatic N-Nitrosoureas,”Revew Roumaine de Chimie22(6):885-898.
Johnston et al., 1966, “The Synthesis of Potential Anticancer Agents. XXXVI. N-Nitrosoureas. II. Haloalkyl Derivatives,”J. Med. Chem. 9(6):892-910.
Chen Guangming
Hwang Seongwoo
Takasugi James J.
Welch Ellen M.
Wilde Richard G.
Jones Day
PTC Therapeutics, Inc.
Shiao Rei-Tsang
LandOfFree
Ureido substituted benzoic acid compounds and their use for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ureido substituted benzoic acid compounds and their use for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ureido substituted benzoic acid compounds and their use for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926576